

These documents have been translated from Japanese originals for reference purposes only. In the event of any discrepancy between these translated documents and the Japanese originals, the originals shall prevail.



July 14, 2021

## NIHON KOHDEN CORPORATION (6849)

Stock Exchange Listing: 1<sup>st</sup> section Tokyo Stock Exchange  
Head Office: Tokyo  
Representative: Hirokazu Ogino, Representative Director, President  
Contact: Keichiro Yoshizawa, General Manager, Corporate Strategy Division  
Phone: +81 / 3-5996 - 8003

### Nihon Kohden Announces its Consolidated Financial Forecast for the First Quarter of Fiscal 2021

Based on recent performance trends, Nihon Kohden hereby announces that there are expected to be differences between its consolidated financial forecasts for the 1<sup>st</sup> quarter of the fiscal year ending March 31, 2022 and its consolidated financial results for the same period of the previous fiscal year.

#### 1. Differences between Consolidated Financial Forecasts for the 1<sup>st</sup> Quarter of FY2021 (From April 1, 2021 to June 30, 2021) and Financial Results for the 1<sup>st</sup> Quarter of FY2020

	Net Sales	Operating Income	Ordinary Income	Income attributable to owners of parent	EPS
	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Yen
Results for 1Q of FY2020 (A)	38,461	1,831	1,581	1,060	12.46
Forecasts for 1Q of FY2021 (B)	46,500	6,000	6,000	4,000	47.23
Difference (B-A)	8,039	4,169	4,419	2,940	
Difference as percentage (%)	20.9	227.7	279.5	277.4	
(Reference) FY2020 (ended March 31, 2021)	199,727	27,094	28,374	18,243	214.21

#### 2. Reasons for the Differences

The Company expects both domestic and overseas sales in the 1<sup>st</sup> quarter of FY2021 to increase significantly. Demand for certain products such as Physiological Measuring Equipment has recovered from the same period of the previous fiscal year, when the number of testing and surgical procedures decreased due to the COVID-19 pandemic. In Japan, sales of Patient Monitors showed strong growth, as the Government's supplementary budget has continued to support demand in healthcare systems. Internationally, sales of Patient Monitors also increased favorably, thanks to receiving large orders in the U.S. as well as strong demand in India and Latin America due to the resurgence of COVID-19.

Income is also expected to increase significantly compared to the same period of the previous fiscal year, due to the positive effect of increased sales and higher gross profit margin.

Forecasts for the full-year and the 1<sup>st</sup> half of FY2021 are currently under review and will be released at the time of the announcement of the 1<sup>st</sup> quarter of FY2021 results scheduled on August 4, 2021.

\*The above estimates are based on information available on the date of this report's announcement. Actual results may differ from such estimates due to unforeseen circumstances.